Phase III Data AFFIRM Safety As Well As Survival For MDV3100
This article was originally published in The Pink Sheet Daily
Executive Summary
Medivation’s MDV3100 demonstrates a favorable safety profile and hits secondary efficacy endpoints in the AFFIRM study. Drug does not need to be given with prednisone, and could give J&J’s recently launched Zytiga a run for its money.
You may also be interested in...
Astellas/Medivation Strengthen Case For Xtandi In Advance Of Second Filing
New PSA data from the AFFFIRM trial in post-chemo patients indicate prostate cancer drug Xtandi works equally well regardless how advanced the disease, a meaningful finding for heavily pretreated patients like those in the trial. Interim rPFS data from a chemo-naïve study will be available in the second half of 2013, but a supplemental filing most certainly will wait for overall survival results.
Medivation/Astellas’ Xtandi A Tough Rival For J&J’s Zytiga
Medivation/Astellas’ Xtandi was approved barely a month after FDA announced it had accepted its NDA for post-chemo castration-resistant metastatic prostate cancer, and the newly approved androgen blocker appears to have what it takes to unseat J&J’s market leader Zytiga.
Xtandi Gets Speedy Approval; Medivation/Astellas Already Prepped For Launch
FDA announced approval of Medivation/Astellas’ androgen receptor inhibitor Xtandi (enzalutamide) a little over three months after the NDA for metastatic castration-resistant prostate cancer was submitted, and the sponsors expect to begin promotions shortly after the U.S. Labor Day holiday.